Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00322023 · ClinicalTrials.gov registry record · Phase 2
Safety and Effectiveness of D-serine in Schizophrenia
A Phase 2 study, sponsored by Nathan Kline Institute for Psychiatric Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
NCT00322023 is a Phase 2 study that has completed, run by Nathan Kline Institute for Psychiatric Research. The registered enrollment target is 55 participants.
The verdict
NCT00322023, a Phase 2 study, has completed, sponsored by Nathan Kline Institute for Psychiatric Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
Study Summary
This study will determine whether increasing D-serine within the body will improve negative symptoms and cognitive impairments in people with schizophrenia.
Interventions
- DRUG D-serine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2006-03 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00322023
The ClinicalTrials.gov registry entry for NCT00322023 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nathan Kline Institute for Psychiatric Research, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which D-serine is the first listed.
NCT00322023 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00322023 about?
NCT00322023 is a clinical study titled "Safety and Effectiveness of D-serine in Schizophrenia". This study will determine whether increasing D-serine within the body will improve negative symptoms and cognitive impairments in people with schizophrenia.
What is the current status of trial NCT00322023?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2006-03. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00322023?
The interventions under investigation include: D-serine (DRUG).
Who is sponsoring clinical trial NCT00322023?
This trial is sponsored by Nathan Kline Institute for Psychiatric Research, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.